EXICURE INC (XCUR)
US30205M2008 - Common Stock
Taking everything into account, XCUR scores 1 out of 10 in our fundamental rating. XCUR was compared to 568 industry peers in the Biotechnology industry. While XCUR seems to be doing ok healthwise, there are quite some concerns on its profitability. XCUR has a expensive valuation and it also scores bad on growth.
1. Profitability
1.1 Basic Checks
In the past year XCUR has reported negative net income.
XCUR had a negative operating cash flow in the past year.
In the past 5 years XCUR always reported negative net income.
In the past 5 years XCUR reported 4 times negative operating cash flow.
1.2 Ratios
Looking at the Return On Assets, with a value of -37.69%, XCUR is in line with its industry, outperforming 59.82% of the companies in the same industry.
Looking at the Return On Equity, with a value of -259.35%, XCUR is doing worse than 71.68% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -37.69% | ||
| ROE | -259.35% | ||
| ROIC | N/A |
ROA(3y)-85.3%
ROA(5y)-60.66%
ROE(3y)-382.56%
ROE(5y)-244.07%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
XCUR does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
XCUR does not have a ROIC to compare to the WACC, probably because it is not profitable.
XCUR has less shares outstanding than it did 1 year ago.
Compared to 5 years ago, XCUR has more shares outstanding
There is no outstanding debt for XCUR. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
XCUR has an Altman-Z score of -23.89. This is a bad value and indicates that XCUR is not financially healthy and even has some risk of bankruptcy.
With a Altman-Z score value of -23.89, XCUR is not doing good in the industry: 89.03% of the companies in the same industry are doing better.
There is no outstanding debt for XCUR. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -23.89 |
ROIC/WACCN/A
WACC11.63%
2.3 Liquidity
A Current Ratio of 0.71 indicates that XCUR may have some problems paying its short term obligations.
XCUR's Current ratio of 0.71 is on the low side compared to the rest of the industry. XCUR is outperformed by 91.50% of its industry peers.
XCUR has a Quick Ratio of 0.71. This is a bad value and indicates that XCUR is not financially healthy enough and could expect problems in meeting its short term obligations.
The Quick ratio of XCUR (0.71) is worse than 91.50% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.71 | ||
| Quick Ratio | 0.71 |
3. Growth
3.1 Past
The earnings per share for XCUR have decreased strongly by -231.93% in the last year.
Looking at the last year, XCUR shows a very negative growth in Revenue. The Revenue has decreased by -97.70% in the last year.
EPS 1Y (TTM)-231.93%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%5.47%
Revenue 1Y (TTM)-97.7%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
3.2 Future
No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. Valuation
4.1 Price/Earnings Ratio
XCUR reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A
5. Dividend
5.1 Amount
No dividends for XCUR!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
EXICURE INC
NASDAQ:XCUR (12/18/2024, 8:00:02 PM)
Premarket: 17.5 -0.06 (-0.34%)17.56
-0.97 (-5.23%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners2.61%
Inst Owner Change-85.93%
Ins Owners810.63%
Ins Owner Change1.12%
Market Cap45.83M
Analysts43.33
Price Target2.04 (-88.38%)
Short Float %8.09%
Short Ratio0.1
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 91.66 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 29.66 | ||
| P/tB | 29.66 | ||
| EV/EBITDA | N/A |
EPS(TTM)-2.26
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-1.1
FCFYN/A
OCF(TTM)-1.1
OCFYN/A
SpS0.19
BVpS0.59
TBVpS0.59
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -37.69% | ||
| ROE | -259.35% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)-85.3%
ROA(5y)-60.66%
ROE(3y)-382.56%
ROE(5y)-244.07%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0.05
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | N/A | ||
| Cap/Sales | N/A | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 0.71 | ||
| Quick Ratio | 0.71 | ||
| Altman-Z | -23.89 |
F-Score2
WACC11.63%
ROIC/WACCN/A
Cap/Depr(3y)29.16%
Cap/Depr(5y)155.22%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-231.93%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%5.47%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-97.7%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-183.2%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y93.23%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y93.17%
OCF growth 3YN/A
OCF growth 5YN/A